In the first of a series of articles the authors of a King's Fund report on polypharmacy outline the scale of the issue and how medicines optimisation could be used to mitigate against the problem
No takes yet. Share an insight, caveat, or question.
Duerden et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: